Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. Hartung, F. Lublin, H. McFarland, D. Paty, C. Polman, S. Reingold, M. Sandberg-wollheim, W. Sibley, A. Thompson, S. Noort, B. Weinshenker, J. Wolinsky (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 50
J. Mandrioli, P. Sola, R. Bedin, M. Gambini, E. Merelli (2008)
A multifactorial prognostic index in multiple sclerosisJournal of Neurology, 255
J. Kurtzke (1983)
Rating neurologic impairment in multiple sclerosisNeurology, 33
C Cordonnier, J de Seze, G Breteau (2003)
Prospective study of patients presenting with acute partial transverse myelopathy., 250
LD Jacobs, RW Beck, JH Simon (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis., 343
R. Schneider, B. Euler, S. Rauer (2007)
Intrathecal IgM‐synthesis does not correlate with the risk of relapse in patients with a primary demyelinating eventEuropean Journal of Neurology, 14
M. Tintoré, A. Rovira, J. Río, C. Nos, E. Grivé, N. Téllez, R. Pelayo, M. Comabella, J. Sastre-Garriga, X. Montalban (2006)
Baseline MRI predicts future attacks and disability in clinically isolated syndromesNeurology, 67
T. Scott, Salima Kassab, Shalu Singh (2005)
Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosisMultiple Sclerosis, 11
J. Bruna, S. Martínez-Yélamos, A. Martínez-Yélamos, F. Rubio, T. Arbizu (2006)
Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 casesMultiple Sclerosis, 12
L. Villar, Jaime Masjuan, P. Gónzalez-Porqué, P. Jf, M. Sádaba, E. Roldán, A. Bootello, J. Álvarez-cermeño (2002)
Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MSNeurology, 59
JF Kurtzke (1983)
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)., 33
J. Sellner, N. Lüthi, R. Bühler, A. Gebhardt, O. Findling, I. Greeve, H. Mattle (2008)
Acute partial transverse myelitis: risk factors for conversion to multiple sclerosisEuropean Journal of Neurology, 15
C. Cordonnier, J. Seze, G. Breteau, D. Ferriby, E. Michelin, T. Stojkovic, J. Pruvo, P. Vermersch (2003)
Prospective study of patients presenting with acute partial transverse myelopathyJournal of Neurology, 250
J. Seze, T. Stojkovic, Guillaume Breteau, C. Lucas, Ulrich Michon-Pasturel, J. Gauvrit, E. Hachulla, F. Mounier-Véhier, J. Pruvo, D. Leys, A. Destée, P. Hatron, P. Vermersch (2001)
Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases.Brain : a journal of neurology, 124 Pt 8
M. Harzheim, U. Schlegel, H. Urbach, T. Klockgether, S. Schmidt (2004)
Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patientsJournal of the Neurological Sciences, 217
F. Barkhof, M. Filippi, David Miller, P. Scheltens, A. Campi, C. Polman, G. Comi, H. Adèr, N. Losseff, J. Valk (1997)
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.Brain : a journal of neurology, 120 ( Pt 11)
B. Ford, D. Tampieri, G. Francis (1992)
Long‐term follow‐up of acute partial transverse myelopathyNeurology, 42
Lawrence Jacobs, Roy Beck, J. Simon, R. Kinkel, C. Brownscheidle, T. Murray, N. Simonian, P. Slasor, Alfred Sandrock (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.The New England journal of medicine, 343 13
L. Kappos, M. Freedman, C. Polman, G. Edan, H. Hartung, David Miller, X. Montalban, F. Barkhof, E. Radü, L. Bauer, S. Dahms, V. Lanius, C. Pohl, R. Sandbrink (2007)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyThe Lancet, 370
M. Brodsky, S. Nazarian, S. Orengo‐Nania, G. Hutton, E. Buckley, E. Massey, M. Bhatti, M. Greer, J. Goodwin, M. Wall, P. Savino, T. Leist, N. Miller, D. Irani, J. Trobe, W. Cornblath, D. Kaufman, E. Eggenberger, M. Kupersmith, W. Shults, L. McAllister, S. Hamilton, R. Beck, M. Dontchev, R. Gal, C. Kollman, J. Keltner, Craig Smith (2008)
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.Archives of neurology, 65 6
P. Brex, O. Ciccarelli, J. O'riordan, M. Sailer, A. Thompson, David Miller (2002)
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.The New England journal of medicine, 346 3
J Mandrioli, P Sola, R Bedin, M Gambini, E Merelli (2008)
A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease., 255
L. Fisniku, P. Brex, Daniel Altmann, K. Miszkiel, C. Benton, R. Lanyon, A. Thompson, David Miller (2008)
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.Brain : a journal of neurology, 131 Pt 3
ORIGINAL CONTRIBUTION Long-term Follow-up of Acute Partial Transverse Myelitis Bertrand Bourre, MD; He´lène Ze´phir, MD; Jean-Claude Ongagna, CRA; Charlotte Cordonnier, MD, PhD; Nicolas Collongues, MD; Stephanie Debette, MD; Marie-Celine Fleury, MD; Olivier Outteryck, MD; Didier Hannequin, MD, PhD; Patrick Vermersch, MD, PhD; Jerome de Seze, MD, PhD Background: Acute partial transverse myelitis (APTM) (33%), with a mean (SD) age at onset of 36.7 (11.7) years. may be the first clinical symptom of multiple sclerosis At the end of follow-up, 53 patients (62%) were classi- (MS) or may remain a monophasic event. fied as having MS with a mean (SD) Expanded Disabil- ity Status Scale score of 2.6 (1.8), 1 patient (1%) was clas- Objectives: To evaluate the risk of conversion to MS sified as having postinfectious myelitis, 1 (1%) as having and long-term disability, and to determine prognosis fac- neuromyelitis optica, 1 (1%) as having Sjo ¨ gren syn- tors for disability. drome, and 29 (34%) still had APTM of undetermined etiology. Oligoclonal bands in CSF were more frequent Design: We identified patients with no previous his- in patients with MS (92%) than in patients with APTM tory of neurological disease who experienced APTM be- of undetermined etiology (38%).
JAMA Neurology – American Medical Association
Published: Mar 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.